CEO & Managing Director and Appointment of Acting CEO The Board has today accepted Michael Knaap’s resignation as Chief Executive Officer and

Managing Director of Monash IVF Group. Mr. Knaap also resigned as a director of Monash IVF Group Limited.

The Board acknowledges and respects his decision.

Since his appointment in 2019, Michael has led the organisation through a period of significant

growth and transformation, and we thank him for his years of dedicated service.

Monash IVF Group Chief Financial Officer and Company Secretary, Malik Jainudeen has been appointed as Acting Chief Executive Officer.

Malik Jainudeen - Biography Malik Jainudeen brings over a decade of service to Monash IVF Group, having joined in 2014 and serving as Chief Financial Officer and Company Secretary since 2019. His deep understanding of the organisation's operations, positions him as a steady and capable leader during this transitional period. With a background that includes ten years at KPMG managing audits for major ASX-listed companies, Malik combines financial understanding with a comprehensive knowledge of the healthcare sector.

In the interim, Malik Jainudeen’s remuneration will remain as stated on page 57 of the 2024Annual Report until further notice.

Authorised by the Board of Directors.

Embryo transfer incident at Clayton laboratory Monash IVF Group Limited (ASX : MVF, the “Company” or “Monash IVF”) advises that an incident at the Clayton laboratory (Incident) occurred on Thursday 5 June where a patient's own embryo was incorrectly transferred to that patient, contrary to the treatment plan which designated the transfer of an embryo of the patient's partner. Monash IVF has extended its sincere apologies to the affected couple, and we continue to support them. Monash IVF is conducting an internal investigation into the Incident. It has also extended the scope of the independent review being conducted by Fiona McLeod AO SC in relation to the Brisbane incident (as announced on 10 April 2025), noting that the different incidents occurred some years apart. Monash IVF will provide an update on the findings of the expanded review in due course. Commencing immediately, Monash IVF will implement interim additional verification processes and patient confirmation safeguards over and above normal practice and electronic witness systems, to ensure patients and clinicians have every confidence in its processes. Whilst industry leading electronic witness systems have and are being rolled out across Monash IVF, there remains instances and circumstances whereby manual witnessing is required. Monash IVF has disclosed the Incident to the relevant assisted reproductive technology (ART) regulators, namely the Reproductive Technology Accreditation Committee certifying body and Victorian Health Regulator. In addition, Monash IVF has notified its insurers and expects the Incident to fall within the scope of its insurance coverage. The update on profit guidance given by Monash IVF on 20 May 2025 remains unchanged. Monash IVF will keep the ASX informed of any developments, if necessary. Authorised by the Board of Directors. QUEENSLAND FERTILITY GROUP QFG spokesperson: 

• This involves an ongoing civil claim and we are unable to comment on the specifics. We continue to work towards a resolution.
• Today, QFG clinics use an electronic tracking and witnessing system - for identifying and digitally tracking eggs, sperm and embryos in the IVF lab - as well as verification by two scientists.
• Our clinics take every possible precaution and comply with applicable regulations.
• QFG is privileged to have helped thousands of Australian families to conceive.